Impact of medical therapy on patients with Crohn’s disease requiring surgical resection

Table 2 Demographic and Surgical details for patients treated with and without anti-tumor necrosis factoragents in years 2005-2010 (cohort B)

	Anti-TNF (n = 38)	Without Anti-TNF (n = 76)	P value
Age	29.5 (± 13.14)	33.5 (± 14.05)	0.10
Gender (M/F)	60.5 (23)/39.5 (15)	51.3 (39)/48.7 (37)	0.35
Smoking status (yes)	26.3 (10)	23.7 (18)	0.82
Montreal classification
Age at diagnosis (A1/A2/A3)	39.5%/50%/10.5%	11.8%/73.7%/14.5%	0.003
Disease behavior (B1/B2/B3)	18.4%/39.5%/42.1%	9.2%/48.7%/42.1%	0.33
Disease location (L1/L2/L3)	23.7%/29%/47.4%	27.6%/7.9%/64.5%	0.01
Medication exposure
5-ASA	29 (11)	30.3 (23)	0.88
CS	81.6 (31)	72.4 (55)	0.28
IM	79 (30)	44.7 (34)	0.001
Surgical details
Time from diagnosis to surgery (mo)	90 ± 63.1	48 ± 100.2	0.02
Amount of small bowel resected (cm)	23 ± 12.4	21.5 ± 19.3	0.92
Length of hospital stay (d)	9 ± 8.6	10 ± 7.7	0.76

Data are expressed as absolute numbers (percentage) or mean ± SD. 5-ASA: 5-aminosalysilic acid; CS: Corticosteroid; IM: Immunomodulator; M: Male; F: Female.